Bristol-Myers Squibb Company BMY
Composite 68/100; the shares have moved about 28% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Its least supportive area is Valuation at 56 — still above average.
Quality ranks 82/100 — a strong point in its favour. Income ranks 80/100 — a strong point in its favour. Momentum ranks 76/100 — a strong point in its favour.
Its least supportive area is Valuation at 56 — still above average.
What the company does Bristol-Myers Squibb (BMY) discovers, develops, and commercializes biopharmaceuticals across oncology, immunology, cardiovascular, and neuroscience. Key products include Opdivo (cancer), Eliquis (stroke risk reduction), and Breyanzi (lymphoma therapy).
Key financials BMY reports ROE 47%, ROA 11%, and ROCE 20%, with net margins at 19%. Revenue growth is flat at -0% while EPS surged 153%. Debt/Equity stands at 2.02x, with interest coverage of 7.9x and a current ratio of 1.53.
Stock health Sideravia scores BMY 68/100, highlighting strong quality (81%) and momentum (73%). Piotroski F-Score is 8/9 and Altman Z is 2.75, indicating robust financial health. Dividend yield is 3.7% with a payout ratio of 39%.
Price vs fair value BMY trades at a PREMIUM of 2.10% versus the analyst mean target of 66.21 (Valuation anchor). - Trading 1.50% below its 52-week high (Momentum). - Recent manufacturing expansion signals long-term capacity growth (Manufacturing Dive). - Dividend highlighted as attractively priced in retail-focused coverage (Motley Fool).
Looking forward Forward P/E of 9.40x and PEG of 0.18 suggest valuation support, though revenue growth remains flat. Pipeline catalysts (e.g., Opdualag, Krazati) and M&A chatter (24/7 Wall St.) may drive sentiment. Momentum remains positive with 47% gains over 12 months.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.